ERBB2 and neoplasm: Overexpression of HER2 protein results in excessive receptor levels on tumor cells and has clinical significance in guiding the use of targeted therapies, such as trastuzumab deruxtecan (T-DXd), that directly inhibit HER2-driven oncogenic signaling [186].